Coupling Aptamers to Short Interfering RNAs as Therapeutics
Open Access
- 27 October 2011
- journal article
- review article
- Published by MDPI AG in Pharmaceuticals
- Vol. 4 (11), 1434-1449
- https://doi.org/10.3390/ph4111434
Abstract
RNA-based approaches are among the most promising strategies aimed at developing safer and more effective therapeutics. RNA therapeutics include small non-coding miRNAs, small interfering RNA, RNA aptamers and more recently, small activating RNAs. However, major barriers exist to the use of RNAs as therapeutics such as resistance to nucleases present in biological fluids, poor chemical stability, need of specific cell targeted delivery and easy entry into the cell. Such issues have been addressed by several recent reports that show the possibility of introducing chemical modifications in small RNAs to stabilize the molecular conformation and increase by several fold their integrity, while still preserving the functional activity. Further, several aptamers have been developed as excellent candidates for the specific recognition of cell surface targets. In the last few years, by taking advantage of recent advances in the small RNA field, molecular bioconjugates have been designed that permit specific targeting and may act as cargoes for cell internalization of small RNAs acting on gene expression that will be discussed in this review.This publication has 89 references indexed in Scilit:
- Therapeutic Inhibition of miR-208a Improves Cardiac Function and Survival During Heart FailureCirculation, 2011
- Delivery of siRNA Therapeutics: Barriers and CarriersThe AAPS Journal, 2010
- Aptamer-Based Detection of Epithelial Tumor Marker Mucin 1 with Quantum Dot-Based Fluorescence ReadoutAnalytical Chemistry, 2009
- Novel Dual Inhibitory Function Aptamer–siRNA Delivery System for HIV-1 TherapyMolecular Therapy, 2008
- The Nucleolin Targeting Aptamer AS1411 Destabilizes Bcl-2 Messenger RNA in Human Breast Cancer CellsCancer Research, 2008
- MicroRNA-21 targets tumor suppressor genes in invasion and metastasisCell Research, 2008
- Cell type–specific delivery of siRNAs with aptamer-siRNA chimerasNature Biotechnology, 2006
- Argonaute2 Cleaves the Anti-Guide Strand of siRNA during RISC ActivationCell, 2005
- Extensive modulation of a set of microRNAs in primary glioblastomaBiochemical and Biophysical Research Communications, 2005
- Derivation of RNA aptamer inhibitors of human complement C5Immunopharmacology, 1999